<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="7168">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 13, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00950859</url>
  </required_header>
  <id_info>
    <org_study_id>112961</org_study_id>
    <nct_id>NCT00950859</nct_id>
  </id_info>
  <brief_title>A Pilot Study Assessing the Integrase Inhibitor GSK1349572 in HIV-infected Persons With Virus Resistant to Raltegravir</brief_title>
  <official_title>A Pilot Study to Assess the Antiviral Activity of GSK1349572 Containing Regimen in Antiretroviral Therapy (ART)-Experienced, HIV-1-infected Adult Subjects With Raltegravir Resistance</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>ViiV Healthcare</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>ViiV Healthcare</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Integrase is an enzyme produced by HIV so that the virus can multiply in the human body.
      GSK1349572 is a new drug in the integrase inhibitor class that prevents the enzyme from
      working properly and therefore prevents the virus from multiplying.

      GSK1349572 has shown to be effective against viruses in a short-term monotherapy study in
      adults with no previous exposure to integrase inhibitors. The purpose of this study is to
      determine whether GSK1349572 is effective in the treatment of HIV-infected patients who no
      longer respond to treatment with the approved integrase inhibitor raltegravir and carry
      viruses with resistance to this drug. The safety and efficacy of GSK1349572 50mg once daily
      in combination with the background HIV drugs previously administered (unless discontinuation
      of a particular drug is required) will be assessed over 10 days (functional monotherapy
      phase), followed by the evaluation of the safety and efficacy of GSK1349572 given with a new
      optimised background regimen from Day 11 through at least Week 24.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study (ING112961) is a Phase IIb, multicentre, open-label, single arm, two cohorts, pilot
      study to assess the antiviral activity of GSK1349572 containing regimen in HIV-1 infected
      ART-experienced adults with raltegravir (RAL) resistance. The study will include
      approximately 50 ART-experienced subjects with either current or past virologic failure to
      RAL. All subjects must harbour isolates with RAL resistance mutations at Screening. Subjects
      should also have documented genotypic and/or phenotypic resistance to at least one compound
      from each of three or more of the approved classes of ART (including integrase inhibitors
      [INIs]). Subjects with current RAL virologic failure will substitute RAL with GSK1349572
      50mg once daily and continue the remaining components of their failing regimen through Day
      10. Subjects with historical RAL virologic failure will add GSK1349572 50mg once daily to
      their failing regimen through Day 10. On Day 11 all subjects will continue GSK1349572 and
      optimize their background therapy. Antiviral activity, safety and tolerability of GSK1349572
      will be evaluated at Day 11 and over time through at least Week 24.

      ViiV Healthcare is the new sponsor of this study, and GlaxoSmithKline is in the process of
      updating systems to reflect the change in sponsorship.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2009</start_date>
  <completion_date type="Actual">January 2015</completion_date>
  <primary_completion_date type="Actual">November 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Number of Participants Who Achieved HIV-1 RNA &lt;400 Copies (c)/Milliliter (mL) or at Least 0.7 log10 c/mL Below Their Baseline Value at Day 11</measure>
    <time_frame>Baseline (Day 1) and Day 11</time_frame>
    <safety_issue>No</safety_issue>
    <description>The number of participants who acheived Plasma Human Immunodeficiency Virus-1 (HIV-1) Ribonucleic Acid (RNA) &lt;400 c/mL or at least 0.7 log10 c/mL below their Baseline value at Day 11 was assessed. The last observation was carried forward if a participant had missed the Day 11 visit. The Baseline observation was carried forward if a participant had discontinued the treatment before Day 11. Blood samples for assessment of HIV-1 RNA levels were collected at Baseline and Day 11.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in Plasma HIV-1 RNA at Day 6 to 8, Day 11, Weeks 4, 12, 24, 48, 72, 96, From Week 108 Every 12 Weeks up to Study Completion</measure>
    <time_frame>Baseline; Day 6 to 8; Day 11; Weeks 4, 12, 24, 48, 72, 96, from 108 every 12 weeks up to study completion</time_frame>
    <safety_issue>No</safety_issue>
    <description>Mean change from Baseline in Plasma HIV-1 RNA was assessed on Day 6 to 8, Day 11, and Weeks 4, 12, 24, 48, 72, 96, 108, 120, 132, 144, 156, 168, 180, 192, 204, 216, 228, 240, 252, and 264 using data of the observed cases. Study Day 1 was considered as Baseline. Change from Baseline was calculated as the post-Baseline value minus the Baseline value.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Who Achieved Plasma HIV-1 RNA &lt;400 c/mL and &lt;50 c/mL at Baseline and Weeks 4, 12, 24, 48, 72, and 96: TLOVR Analysis.</measure>
    <time_frame>Baseline; Weeks 4, 12, 24, 48, 72, and 96</time_frame>
    <safety_issue>No</safety_issue>
    <description>The number of participants with plasma HIV-1 RNA &lt;400 c/mL or &lt;50 c/mL was assessed at Weeks 4, 12, 24, 48, 72, and 96 per the Food and Drug Administration's Time to Loss of Virological Response (TLOVR) algorithm. Using the TLOVR algorithm, participants are considered to have failed on therapy if they never achieved confirmed RNA levels below the threshold, if they had confirmed rebound of RNA above the threshold, if they made a non-permitted change in background regimen, or if they permanently discontinued investigational product for any reason.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Participants Who Achieved Plasma HIV-1 RNA &lt;400 c/mL and &lt;50 c/mL From Week 48 Every 12 Weeks up to Study Completion</measure>
    <time_frame>From Week 48 every 12 weeks up to study completion</time_frame>
    <safety_issue>No</safety_issue>
    <description>The number of participants with plasma HIV-1 RNA &lt;400 c/mL or &lt;50 c/mL was assessed at Weeks 48, 72, 96, 108, 120, 132, 144, 156, 168, 180, 192, 204, 216, 228, 240, 252, and 264 using data of observed cases. Only those participants available at the specified time points were analyzed (represented by n=X in the category titles).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in CD4+ Cell Count at Day 11 and Weeks 4, 12, 24, 48, 72, 96, Week 108 Every 12 Weeks up to Study Completion</measure>
    <time_frame>Baseline; Day 11; Weeks 4, 12, 24, 48, 72, 96, from Week 108 every 12 weeks up to study completion</time_frame>
    <safety_issue>No</safety_issue>
    <description>Change from Baseline in CD4+ cell count was assessed at Day 11 and at Weeks 4, 12, 24, 48, 72, 96, 108, 120, 132, 144, 156, 168, 180, 192, 204, 216, 228, 240, 252, and 264 . Study Day 1 was considered as Baseline. Change from Baseline was calculated as the post-Baseline value minus the Baseline value.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax, Cmin, and Ctau of DTG</measure>
    <time_frame>Day 10</time_frame>
    <safety_issue>No</safety_issue>
    <description>The maximum plasma concentration (Cmax), minimum plasma concentration (Cmin), and concentration at the end of a dosing interval (Ctau) of DTG were assessed at Day 10. Blood samples for pharmacokinetic (PK) assessments were collected at pre-dose (within 15 minutes prior to dose) and 2, 3, 4, 8, and 24 hours post-dose on Day 10 for DTG 50 mg OD and pre-dose (within 15 minutes prior to dose) and 2, 3, 4 and 8 hours post morning dose and 12 hours post evening dose for DTG 50 mg BID.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>C0 Assessment of DTG</measure>
    <time_frame>Day 10; Weeks 4 and 24</time_frame>
    <safety_issue>No</safety_issue>
    <description>The plasma DTG concentration immediately prior to dosing at steady state (C0) was assessed at Day 10, and Weeks 4 and 24. Blood samples for pharmacokinetic assessments were collected at pre-dose (within 15 minutes prior to dose).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tmax of DTG</measure>
    <time_frame>Day 10</time_frame>
    <safety_issue>No</safety_issue>
    <description>The tmax is defined as the time of occurrence of the maximum plasma concentration (Cmax). The tmax was assessed at Day 10. Blood samples for pharmacokinetic assessments were collected at pre-dose (within 15 minutes prior to dose) and 2, 3, 4, 8, and 24 hours post-dose on Day 10 for DTG 50 mg OD and pre-dose (within 15 minutes prior to dose) and 2, 3, 4 and 8 hours post morning dose and 12 hours post evening dose for DTG 50 mg BID.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC0-24 Assessment of DTG</measure>
    <time_frame>Day 10</time_frame>
    <safety_issue>No</safety_issue>
    <description>AUC is defined as the area under the DTG concentration-time curve as a measure of drug exposure. AUC(0-24) is defined as the area under the concentration-time curve from time zero (pre-dose) to 24 hours. AUC0-24 of DTG was assessed at Day 10. Blood samples for pharmacokinetic assessments were collected at pre-dose (within 15 minutes prior to dose) and 2, 3, 4, 8, and 24 hours post-dose on Day 10 for DTG 50 mg OD and pre-dose (within 15 minutes prior to dose) and 2, 3, 4 and 8 hours post morning dose and 12 hours post evening dose for DTG 50 mg BID.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With the Indicated HIV-1 Associated Conditions, Excluding Recurrences</measure>
    <time_frame>From the day of the first dose of study drug until study completion (median 605 days for Cohort I, median 1181 days for Cohort II)</time_frame>
    <safety_issue>No</safety_issue>
    <description>The number of participants with post-Baseline emergent HIV-1 disease progression (Acquired immunodeficiency syndrome (AIDS) or death) was assessed per the Centers for Disease Control and Prevention (CDC) 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. The CDC classifies HIV infection as Category A (participants with asymptomatic HIV infection, acute HIV infection with accompanying illness, or persistent generalized lymphadenopathy), Category B (participants with symptomatic non-AIDS condition, i.e., conditions that are attributed to HIV infection or are indicative of a defect in cell-mediated immunity; or conditions are considered by physicians to have a clinical course or to require management that is complicated by HIV infection), and Category C (includes AIDS indicator conditions as defined by diagnostic or presumptive measures).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With HIV-1 Associated Disease Progression With the Indicated Shifts to CDC Class C or Death</measure>
    <time_frame>From the day of the first dose of study drug until study completion (median 605 days for Cohort I, median 1181 days for Cohort II)</time_frame>
    <safety_issue>No</safety_issue>
    <description>The number of participants with HIV-1 disease progression (AIDS or death) was assessed per the CDC 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. The CDC classifies HIV infection as Category A (participants with asymptomatic HIV infection, acute HIV infection with accompanying illness, or persistent generalized lymphadenopathy), Category B (participants with symptomatic non-AIDS condition, i.e., conditions that are attributed to HIV infection or are indicative of a defect in cell-mediated immunity; or conditions are considered by physicians to have a clinical course or to require management that is complicated by HIV infection), and Category C (includes AIDS indicator conditions as defined by diagnostic or presumptive measures).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants (Cumulative) With Protocol-defined Virological Failure (PDVF) at Day 11 and Weeks 8, 12, 16, 20, 24, 32, 40, 48, 60, 72, 84, 96, Week 108 Every 12 Weeks up to Study Completion</measure>
    <time_frame>Day 11; Weeks 8, 12, 16, 20, 24, 32, 40, 48, 60, 72, 84, 96, from Week 108 every 12 weeks up to study completion</time_frame>
    <safety_issue>No</safety_issue>
    <description>PDVF is defined in relation to Baseline plasma HIV-1 RNA levels: at Day 11, a decrease of &lt;0.7 log10 c/mL unless &lt;400 c/mL; at Weeks 8 to &lt;16, a decrease of &lt;1.0 log10 c/mL unless &lt;400 c/mL or an increase of &gt;= 1.0 log10 c/mL from nadir; and at or after Week 16, ≥400 c/mL. PDVF at Day 11 was based on a single plasma HIV-1 RNA evaluation and did not require confirmation. Confirmation testing was required for visits at or after Week 8. For the combination treatment phase, all HIV-1 RNA samples that meet a criterion for suspected PDVF must be confirmed by a second measurement performed at least 1 week but not more than 4 weeks apart from the date of the original sample.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With the Indicated Genotypic Resistance at Baseline</measure>
    <time_frame>Baseline</time_frame>
    <safety_issue>No</safety_issue>
    <description>At Baseline, the integrase genotypic results were used to document resistance to raltegravir (RAL) and for the allocation of participants to one of two genotypic groups according to their RAL signature mutations to ensure a broad range of sensitivity to DTG. These results were not used to pre-define subgroup for analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median Fold Change in Sensitivity to DTG by the Baseline (Day 1) IN Mutational Group</measure>
    <time_frame>Baseline (Day 1)</time_frame>
    <safety_issue>No</safety_issue>
    <description>Summary of median fold change in sensitivity to DTG by Integrase (IN) mutational group was assessed. The IN mutational group comprises of the following mutations: Q148 +2, Q148 +1, mixture (participants with virus containing more than one Y143, Q148 or N155 mutation at Day 1), Y143, N155, other (participants with virus having no mutations at codons 143, 148, or 155 at Day 1). Fold change (FC) is the fold change in 50% Inhibitory Concentration (IC50) relative to the wild-type control virus.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With the Indicated Treatment-emergent Integrase (IN) Mutations Detected at the Time of Protocol-defined Virologic Failure (PDVF) as a Measure of Genotypic Resistance</measure>
    <time_frame>From Baseline (Day 1) until study completion (median 605 days for Cohort I, median 1181 days for Cohort II)</time_frame>
    <safety_issue>No</safety_issue>
    <description>An analysis of changes at specific amino acids in the IN coding region associated with resistance to raltegravir, elvitegravir, or DTG was performed at Day 1 and at the time of PDVF. PDVF is defined in relation to Baseline plasma HIV-1 RNA levels: at Day 11, a decrease of &lt;0.7 log10 c/mL unless &lt;400 c/mL; at Weeks 8 to &lt;16, a decrease of &lt;1.0 log10 c/mL unless &lt;400 c/mL or an increase of &gt;= 1.0 log10 c/mL from nadir; and at or after Week 16, ≥400 c/mL. PDVF at Day 11 was based on a single plasma HIV-1 RNA evaluation and did not require confirmation. Confirmation testing was required for visits at or after Week 8. For the combination treatment phase, all HIV-1 RNA samples that meet a criterion for suspected PDVF must be confirmed by a second measurement performed at least 1 week but not more than 4 weeks apart from the date of the original sample.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With the Indicated Fold Increase in DTG FC (Fold Change in IC50 Relative to Wild-type Virus) Between Baseline and the Time of PDVF, as a Measure of Post-Baseline Phenotypic Resistance</measure>
    <time_frame>From Baseline (Day 1) until study completion (median 605 days for Cohort I, median 1181 days for Cohort II)</time_frame>
    <safety_issue>No</safety_issue>
    <description>The FC in IC50 (50% inhibitory concentration) for DTG relative to wild-type virus was determined for virus isolated at Baseline and at the time of PDVF.The number of participants with the indicated change (ratio) in the two values at the time of PDVF is presented. PDVF is defined in relation to Baseline plasma HIV-1 RNA levels: at Day 11, a decrease of &lt;0.7 log 10 c/mL unless &lt;400 c/mL; at Weeks 8 to &lt;16, a decrease of &lt;1.0 log 10 c/mL unless &lt;400 c/mL or an increase of &gt;=1.0 log 10 c/mL from nadir; and at or after Week 16, ≥400 c/mL . PDVF at Day 11 was based on a single plasma HIV-1 RNA evaluation and did not require confirmation. Confirmation testing was required for visits at or after Week 8. For the combination treatment phase, all HIV-1 RNA samples that meet a criterion for suspected PDVF must be confirmed by a second measurement performed at least 1 week but not more than 4 weeks apart from the date of original sample.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With the Indicated Grade 3 and Grade 4 Clinical Chemistry Toxicities</measure>
    <time_frame>From start of study treatment until the end of treatment visit for each participant, up to Week 264 for Cohort I and up to Week 228 for Cohort II</time_frame>
    <safety_issue>No</safety_issue>
    <description>Hematology and clinical chemistry data were summarized according to Division of AIDS (DAIDS) Table for Grading the Severity of Adult and Pediatric Adverse Events, dated December 2004. Grade 1, Mild; Grade 2, Moderate; Grade 3, Severe; Grade 4, Potentially life-threatening. Data are presented for only those parameters for which an increase to Grade 3 or Grade 4 occurred. The Grade 3 and Grade 4 clinical chemistry toxicities included: Albumin, Alkaline Phosphatase, Amylase, Aspartate Amino Transferase, Carbon dioxide content/Bicarbonate, Creatinine, Creatinine Clearance, Hypercalcemia, Hyperglycaemia, Hyperkalemia, Hypernatremia, Hypocalcemia, Hypoglycaemia, Hypokalemia, Hyponatremia, LDL Cholesterol, Magnesium, Phosphorus inorganic, and Total Bilirubin, Alanine Amino Transferase, Calcium, Chloride, Cholesterol, Creatine Kinase, Direct Bilirubin, Glucose, High Density Lipid (HDL), Cholesterol direct, Lipase, Potassium, Sodium, Total Cholesterol, Triglycerides, Urea/Blood Urine Nitrogen.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With the Indicated Grade 3 and Grade 4 Hematological Toxicities</measure>
    <time_frame>From start of study treatment until the end of treatment visit for each participant, up to Week 264 for Cohort I and up to Week 228 for Cohort II</time_frame>
    <safety_issue>No</safety_issue>
    <description>Hematology and clinical chemistry data were summarized according to Division of AIDS (DAIDS) Table for Grading the Severity of Adult and Pediatric Adverse Events, dated December 2004. Grade 1, Mild; Grade 2, Moderate; Grade 3, Severe; Grade 4, Potentially life-threatening. Data are presented for only those parameters for which an increase to Grade 3 or Grade 4 occurred. The Grade 3 and Grade 4 hematological toxicities included: Hemoglobin, Platelet Count, Total Neutrophils, and White Blood Cell count.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">51</enrollment>
  <condition>Infection, Human Immunodeficiency Virus</condition>
  <arm_group>
    <arm_group_label>GSK1349572 Cohort I</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single Arm, Cohort I</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GSK1349572 Cohort II</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single Arm, Cohort II</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GSK1349572 (Cohort I)</intervention_name>
    <description>50 mg once daily</description>
    <arm_group_label>GSK1349572 Cohort I</arm_group_label>
    <other_name>Dolutegravir</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GSK1349572 (Cohort II)</intervention_name>
    <description>50 mg twice daily</description>
    <arm_group_label>GSK1349572 Cohort II</arm_group_label>
    <other_name>Dolutegravir</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  HIV-1 infected male or female adults at least 18 years of age with a plasma HIV-1 RNA
             &gt; 1,000 copies/mL at study entry. Women capable of becoming pregnant must use
             appropriate contraception during the study (as defined by the protocol)

          -  ART-experienced (defined as on stable ART for at least the last 2 months) and is
             either currently experiencing virologic failure to RAL or experienced virologic
             failure to RAL &gt; 8 weeks prior to Screening

          -  Must have documented RAL genotypic resistance on study entry genotype

          -  Must have documented genotypic or phenotypic resistance to at least one drug from
             each of three or more of all approved classes of ART

          -  For Cohort II, Subjects MUST be able to receive at least one fully active drug as
             part of the Day 11 optimised background regimen

          -  Willing and able to understand and provide signed and dated written informed consent
             prior to screening

        Exclusion Criteria:

          -  Any pre-existing mental, physical, or substance abuse disorder which, which could
             compromise ability to comply with the protocol or compromise subject safety

          -  Women who are pregnant or breastfeeding

          -  An active AIDS-defining condition at the screening visit

          -  Currently take and/or anticipated need for EFV, NVP, FPV/RTV or TPV/RTV during the
             study

          -  Treatment with any of the following medications within 15 days of starting study
             drug, or anticipated to need, during the course of the study: Etravirine (unless
             co-administered with LPV/RTV or DRV/RTV), rifampin, rifabutin, phenytoin,
             phenobarbital, barbiturates, glucocorticoids, modafinil, oxcarbazepine, pioglitazone,
             troglitazone, carbamazepine, St. Johns wort

          -  Previous participation in an experimental drug and/or vaccine trial(s) within 30 days
             or 5 half-lives

          -  History of ongoing or clinically relevant pancreatitis or hepatitis within the
             previous 6 months

          -  Expected to require treatment for HCV infection during the first 24 weeks of the
             study

          -  Evidence of cirrhosis with or without hepatitis viral co-infection

          -  History of upper gastrointestinal bleed and/or active peptic ulcer disease

          -  Screening haemoglobin &lt;10g/dL (100g/L)

          -  Subject suffers from a serious medical condition which could compromise the safety of
             the subject.

          -  Any condition that could interfere with the absorption, distribution, metabolism or
             excretion of the drug or render the subject unable to take oral medication

          -  Screening lipase 3 times the upper limit of normal (ULN)

          -  Any acute or Grade 4 laboratory abnormality at screening

          -  Screening alanine aminotransferase (ALT) &gt;5xULN

          -  Screening ALT 3xULN and bilirubin 1.5xULN (with 35% direct bilirubin)

          -  Personal or family history of prolonged QT syndrome.

          -  Any clinically significant finding, as specified in the protocol, on screening or
             baseline electrocardiograph (ECG)

          -  History of allergy to the study drugs or their components or drugs of their class

          -  Treatment with radiation therapy or cytotoxic chemotherapeutic agents within 28 days
             prior to screening, or future need of treatment with these agents during the study

          -  Treatment with immunomodulators within 28 days prior to screening or subject has
             received an HIV-1 vaccine within 90 days prior to screening
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>ViiV Healthcare</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85012</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Long Beach</city>
        <state>California</state>
        <zip>90813</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80220</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20007</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Fort Lauderdale</city>
        <state>Florida</state>
        <zip>33308</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Fort Lauderdale</city>
        <state>Florida</state>
        <zip>33316</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32804</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Santa Fe</city>
        <state>New Mexico</state>
        <zip>87505</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27514</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28209</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75246</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2N2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H3G 1A4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Bordeaux</city>
        <zip>33000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Le Kremlin-Bicêtre Cedex</city>
        <zip>94275</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Lyon Cedex 03</city>
        <zip>69437</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Marseille</city>
        <zip>13009</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Montpellier Cedex 5</city>
        <zip>34295</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Nice</city>
        <zip>06202</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Paris Cedex 13</city>
        <zip>75651</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Milano</city>
        <state>Lombardia</state>
        <zip>20127</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Badalona</city>
        <zip>08916</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Barcelona</city>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Madrid</city>
        <zip>28029</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Sevilla</city>
        <zip>41013</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>France</country>
    <country>Italy</country>
    <country>Spain</country>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Eron JJ, Clotet B, Durant J, Katlama C, Kumar P, Lazzarin A, Poizot-Martin I, Richmond G, Soriano V, Ait-Khaled M, Fujiwara T, Huang J, Min S, Vavro C, Yeo J; VIKING Study Group. Safety and efficacy of dolutegravir in treatment-experienced subjects with raltegravir-resistant HIV type 1 infection: 24-week results of the VIKING Study. J Infect Dis. 2013 Mar 1;207(5):740-8. doi: 10.1093/infdis/jis750. Epub 2012 Dec 7.</citation>
    <PMID>23225901</PMID>
  </reference>
  <verification_date>September 2015</verification_date>
  <lastchanged_date>November 5, 2015</lastchanged_date>
  <firstreceived_date>July 23, 2009</firstreceived_date>
  <firstreceived_results_date>August 15, 2013</firstreceived_results_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>treatment experienced</keyword>
  <keyword>HIV Infection</keyword>
  <keyword>raltegravir resistance</keyword>
  <keyword>GSK1349572</keyword>
  <keyword>optimized background regimen</keyword>
  <keyword>integrase inhibitor</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
    <mesh_term>HIV Infections</mesh_term>
    <mesh_term>Immunologic Deficiency Syndromes</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Dolutegravir</mesh_term>
    <mesh_term>Integrase Inhibitors</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants recruited initially to Cohort I and subsequently to Cohort II. Recruitment to Cohort I was closed 9 months before recruitment to Cohort II was opened. Recruitment was not randomized.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Cohort I (DTG 50 mg OD)</title>
          <description>Participants received dolutegravir (DTG) 50 milligrams (mg) once a day (OD).</description>
        </group>
        <group group_id="P2">
          <title>Cohort II (DTG 50 mg BID)</title>
          <description>Participants received DTG 50 mg twice a day (BID).</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="27"/>
                <participants group_id="P2" count="24"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="14"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
                <participants group_id="P2" count="10"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Insufficient Viral Load Response</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Cohort I (DTG 50 mg OD)</title>
          <description>Participants received dolutegravir (DTG) 50 milligrams (mg) once a day (OD).</description>
        </group>
        <group group_id="B2">
          <title>Cohort II (DTG 50 mg BID)</title>
          <description>Participants received DTG 50 mg twice a day (BID).</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <measure_list>
        <measure>
          <title>Number of Participants</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="27"/>
                <measurement group_id="B2" value="24"/>
                <measurement group_id="B3" value="51"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age, Customized</title>
          <units>Years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <category_list>
            <category>
              <sub_title>Years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="48" lower_limit="19" upper_limit="61"/>
                <measurement group_id="B2" value="47" lower_limit="33" upper_limit="68"/>
                <measurement group_id="B3" value="47" lower_limit="19" upper_limit="68"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Female</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="2"/>
                <measurement group_id="B2" value="6"/>
                <measurement group_id="B3" value="8"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Male</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="25"/>
                <measurement group_id="B2" value="18"/>
                <measurement group_id="B3" value="43"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>African American/African Heritage</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="3"/>
                <measurement group_id="B2" value="5"/>
                <measurement group_id="B3" value="8"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>White-Arabic/North African Heritage</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="1"/>
                <measurement group_id="B2" value="1"/>
                <measurement group_id="B3" value="2"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>White-White/Caucasian/European Heritage</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="23"/>
                <measurement group_id="B2" value="18"/>
                <measurement group_id="B3" value="41"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants Who Achieved HIV-1 RNA &lt;400 Copies (c)/Milliliter (mL) or at Least 0.7 log10 c/mL Below Their Baseline Value at Day 11</title>
        <description>The number of participants who acheived Plasma Human Immunodeficiency Virus-1 (HIV-1) Ribonucleic Acid (RNA) &lt;400 c/mL or at least 0.7 log10 c/mL below their Baseline value at Day 11 was assessed. The last observation was carried forward if a participant had missed the Day 11 visit. The Baseline observation was carried forward if a participant had discontinued the treatment before Day 11. Blood samples for assessment of HIV-1 RNA levels were collected at Baseline and Day 11.</description>
        <time_frame>Baseline (Day 1) and Day 11</time_frame>
        <safety_issue>No</safety_issue>
        <population>Intent-to-Treat Exposed (ITT-E) Population: all participants who received at least one dose of study medication and who had at least one post-Baseline measure of plasma HIV-1 RNA.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort I (DTG 50 mg OD)</title>
            <description>Participants received dolutegravir (DTG) 50 milligrams (mg) once a day (OD).</description>
          </group>
          <group group_id="O2">
            <title>Cohort II (DTG 50 mg BID)</title>
            <description>Participants received DTG 50 mg twice a day (BID).</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="27"/>
                  <measurement group_id="O2" value="24"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Participants Who Achieved HIV-1 RNA &lt;400 Copies (c)/Milliliter (mL) or at Least 0.7 log10 c/mL Below Their Baseline Value at Day 11</title>
            <description>The number of participants who acheived Plasma Human Immunodeficiency Virus-1 (HIV-1) Ribonucleic Acid (RNA) &lt;400 c/mL or at least 0.7 log10 c/mL below their Baseline value at Day 11 was assessed. The last observation was carried forward if a participant had missed the Day 11 visit. The Baseline observation was carried forward if a participant had discontinued the treatment before Day 11. Blood samples for assessment of HIV-1 RNA levels were collected at Baseline and Day 11.</description>
            <units>Participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="21"/>
                  <measurement group_id="O2" value="23"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority>No</non_inferiority>
            <param_type>percentage of participants</param_type>
            <param_value>78</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>58</ci_lower_limit>
            <ci_upper_limit>91</ci_upper_limit>
            <estimate_desc>The estimated value represents the percentage of participants with HIV-1 RNA &lt;400 c/mL or at least 0.7 log10 c/mL below their Baseline value at Day 11.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority>No</non_inferiority>
            <param_type>percentage of participants</param_type>
            <param_value>96</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>79</ci_lower_limit>
            <ci_upper_limit>100</ci_upper_limit>
            <estimate_desc>The estimated value represents the percentage of participants with HIV-1 RNA &lt;400 c/mL or at least 0.7 log10 c/mL below their Baseline value at Day 11.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline in Plasma HIV-1 RNA at Day 6 to 8, Day 11, Weeks 4, 12, 24, 48, 72, 96, From Week 108 Every 12 Weeks up to Study Completion</title>
        <description>Mean change from Baseline in Plasma HIV-1 RNA was assessed on Day 6 to 8, Day 11, and Weeks 4, 12, 24, 48, 72, 96, 108, 120, 132, 144, 156, 168, 180, 192, 204, 216, 228, 240, 252, and 264 using data of the observed cases. Study Day 1 was considered as Baseline. Change from Baseline was calculated as the post-Baseline value minus the Baseline value.</description>
        <time_frame>Baseline; Day 6 to 8; Day 11; Weeks 4, 12, 24, 48, 72, 96, from 108 every 12 weeks up to study completion</time_frame>
        <safety_issue>No</safety_issue>
        <population>ITT-E Population. Only those participants available at the indicated time points were analyzed (represented by n=X, X in the category titles).</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort I (DTG 50 mg OD)</title>
            <description>Participants received dolutegravir (DTG) 50 milligrams (mg) once a day (OD).</description>
          </group>
          <group group_id="O2">
            <title>Cohort II (DTG 50 mg BID)</title>
            <description>Participants received DTG 50 mg twice a day (BID).</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="27"/>
                  <measurement group_id="O2" value="24"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Mean Change From Baseline in Plasma HIV-1 RNA at Day 6 to 8, Day 11, Weeks 4, 12, 24, 48, 72, 96, From Week 108 Every 12 Weeks up to Study Completion</title>
            <description>Mean change from Baseline in Plasma HIV-1 RNA was assessed on Day 6 to 8, Day 11, and Weeks 4, 12, 24, 48, 72, 96, 108, 120, 132, 144, 156, 168, 180, 192, 204, 216, 228, 240, 252, and 264 using data of the observed cases. Study Day 1 was considered as Baseline. Change from Baseline was calculated as the post-Baseline value minus the Baseline value.</description>
            <units>Log10 copies/mL</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <sub_title>Day 6 to 8, n=27, 24</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="-1.31" spread="0.71"/>
                  <measurement group_id="O2" value="-1.40" spread="0.43"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Day 11, n=27, 24</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="-1.45" spread="0.77"/>
                  <measurement group_id="O2" value="-1.76" spread="0.53"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Week 4, n=26, 24</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="-1.82" spread="1.03"/>
                  <measurement group_id="O2" value="-2.06" spread="0.78"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Week 12, n=22, 24</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="-1.94" spread="1.14"/>
                  <measurement group_id="O2" value="-2.30" spread="0.93"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Week 24, n=18, 22</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="-1.99" spread="1.08"/>
                  <measurement group_id="O2" value="-2.50" spread="0.81"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Week 48, n=15, 20</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="-2.02" spread="1.07"/>
                  <measurement group_id="O2" value="-2.63" spread="0.78"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Week 72, n=14, 18</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="-2.10" spread="1.03"/>
                  <measurement group_id="O2" value="-2.71" spread="0.82"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Week 96, n=13, 15</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="-2.06" spread="1.13"/>
                  <measurement group_id="O2" value="-2.58" spread="0.77"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Week 108, n= 13, 17</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="-1.95" spread="1.20"/>
                  <measurement group_id="O2" value="-2.69" spread="0.82"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Week 120, n= 11, 17</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="-2.09" spread="1.15"/>
                  <measurement group_id="O2" value="-2.67" spread="0.85"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Week 132, n= 11, 17</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="-1.83" spread="1.01"/>
                  <measurement group_id="O2" value="-2.66" spread="0.86"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Week 144, n= 12, 15</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="-2.08" spread="1.29"/>
                  <measurement group_id="O2" value="-2.62" spread="0.94"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Week 156, n= 12, 15</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="-2.04" spread="1.36"/>
                  <measurement group_id="O2" value="-2.65" spread="0.77"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Week 168, n= 11, 14</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="-1.77" spread="1.26"/>
                  <measurement group_id="O2" value="-2.72" spread="0.89"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Week 180, n= 11, 10</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="-1.76" spread="1.11"/>
                  <measurement group_id="O2" value="-2.56" spread="0.82"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Week 192, n= 9, 7</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="-1.87" spread="1.16"/>
                  <measurement group_id="O2" value="-2.51" spread="0.98"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Week 204, n= 10, 6</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="-1.76" spread="1.21"/>
                  <measurement group_id="O2" value="-2.35" spread="0.71"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Week 216, n= 9, 6</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="-1.61" spread="1.08"/>
                  <measurement group_id="O2" value="-2.35" spread="0.71"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Week 228, n= 6, 4</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="-1.79" spread="1.08"/>
                  <measurement group_id="O2" value="-2.33" spread="0.90"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Week 240, n= 7, 0</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="-1.63" spread="1.13"/>
                  <measurement group_id="O2" value="NA">Since 0 participants were analyzed, no data to present.</measurement>
                </measurement_list>
              </category>
              <category>
                <sub_title>Week 252, n= 4, 0</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="-1.72" spread="1.07"/>
                  <measurement group_id="O2" value="NA">Since 0 participants were analyzed, no data to present.</measurement>
                </measurement_list>
              </category>
              <category>
                <sub_title>Week 264, n= 1, 0</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="-2.90">As only 1 participant was analyzed; therefore, no SD to present.</measurement>
                  <measurement group_id="O2" value="NA">Since 0 participants were analyzed, no data to present.</measurement>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Who Achieved Plasma HIV-1 RNA &lt;400 c/mL and &lt;50 c/mL at Baseline and Weeks 4, 12, 24, 48, 72, and 96: TLOVR Analysis.</title>
        <description>The number of participants with plasma HIV-1 RNA &lt;400 c/mL or &lt;50 c/mL was assessed at Weeks 4, 12, 24, 48, 72, and 96 per the Food and Drug Administration's Time to Loss of Virological Response (TLOVR) algorithm. Using the TLOVR algorithm, participants are considered to have failed on therapy if they never achieved confirmed RNA levels below the threshold, if they had confirmed rebound of RNA above the threshold, if they made a non-permitted change in background regimen, or if they permanently discontinued investigational product for any reason.</description>
        <time_frame>Baseline; Weeks 4, 12, 24, 48, 72, and 96</time_frame>
        <safety_issue>No</safety_issue>
        <population>ITT-E Population</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort I (DTG 50 mg OD)</title>
            <description>Participants received dolutegravir (DTG) 50 milligrams (mg) once a day (OD).</description>
          </group>
          <group group_id="O2">
            <title>Cohort II (DTG 50 mg BID)</title>
            <description>Participants received DTG 50 mg twice a day (BID).</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="27"/>
                  <measurement group_id="O2" value="24"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Participants Who Achieved Plasma HIV-1 RNA &lt;400 c/mL and &lt;50 c/mL at Baseline and Weeks 4, 12, 24, 48, 72, and 96: TLOVR Analysis.</title>
            <description>The number of participants with plasma HIV-1 RNA &lt;400 c/mL or &lt;50 c/mL was assessed at Weeks 4, 12, 24, 48, 72, and 96 per the Food and Drug Administration's Time to Loss of Virological Response (TLOVR) algorithm. Using the TLOVR algorithm, participants are considered to have failed on therapy if they never achieved confirmed RNA levels below the threshold, if they had confirmed rebound of RNA above the threshold, if they made a non-permitted change in background regimen, or if they permanently discontinued investigational product for any reason.</description>
            <units>Participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>Baseline, &lt;50 c/mL</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Week 4, &lt;50 c/mL</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="9"/>
                  <measurement group_id="O2" value="12"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Week 12, &lt;50 c/mL</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="13"/>
                  <measurement group_id="O2" value="16"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Week 24, &lt;50 c/mL</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="11"/>
                  <measurement group_id="O2" value="19"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Week 48, &lt;50 c/mL</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="9"/>
                  <measurement group_id="O2" value="17"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Week 72, &lt;50 c/mL</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="8"/>
                  <measurement group_id="O2" value="NA">As of the data cut-off, Week 48 is the last time point which all participants in Cohort II would have had opportunity to reach if they had not discontinued prematurely. Only data to Week 48 were therefore analyzed using TLOVR.</measurement>
                </measurement_list>
              </category>
              <category>
                <sub_title>Week 96, &lt;50 c/mL</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="7"/>
                  <measurement group_id="O2" value="NA">As of the data cut-off, Week 48 is the last time point which all participants in Cohort II would have had opportunity to reach if they had not discontinued prematurely. Only data to Week 48 were therefore analyzed using TLOVR.</measurement>
                </measurement_list>
              </category>
              <category>
                <sub_title>Baseline, &lt;400 c/mL</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Week 4, &lt;400 c/mL</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="16"/>
                  <measurement group_id="O2" value="17"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Week 12, &lt;400 c/mL</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="16"/>
                  <measurement group_id="O2" value="20"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Week 24, &lt;400 c/mL</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="14"/>
                  <measurement group_id="O2" value="20"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Week 48, &lt;400 c/mL</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="13"/>
                  <measurement group_id="O2" value="18"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Week 72, &lt;400 c/mL</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="12"/>
                  <measurement group_id="O2" value="NA">As of the data cut-off, Week 48 is the last time point which all participants in Cohort II would have had opportunity to reach if they had not discontinued prematurely. Only data to Week 48 were therefore analysed using TLOVR.</measurement>
                </measurement_list>
              </category>
              <category>
                <sub_title>Week 96, &lt;400 c/mL</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="10"/>
                  <measurement group_id="O2" value="NA">As of the data cut-off, Week 48 is the last time point which all participants in Cohort II would have had opportunity to reach if they had not discontinued prematurely. Only data to Week 48 were therefore analysed using TLOVR.</measurement>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Proportion of Participants Who Achieved Plasma HIV-1 RNA &lt;400 c/mL and &lt;50 c/mL From Week 48 Every 12 Weeks up to Study Completion</title>
        <description>The number of participants with plasma HIV-1 RNA &lt;400 c/mL or &lt;50 c/mL was assessed at Weeks 48, 72, 96, 108, 120, 132, 144, 156, 168, 180, 192, 204, 216, 228, 240, 252, and 264 using data of observed cases. Only those participants available at the specified time points were analyzed (represented by n=X in the category titles).</description>
        <time_frame>From Week 48 every 12 weeks up to study completion</time_frame>
        <safety_issue>No</safety_issue>
        <population>ITT-E Population</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort I (DTG 50 mg OD)</title>
            <description>Participants received dolutegravir (DTG) 50 milligrams (mg) once a day (OD).</description>
          </group>
          <group group_id="O2">
            <title>Cohort II (DTG 50 mg BID)</title>
            <description>Participants received DTG 50 mg twice a day (BID).</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="27"/>
                  <measurement group_id="O2" value="24"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Proportion of Participants Who Achieved Plasma HIV-1 RNA &lt;400 c/mL and &lt;50 c/mL From Week 48 Every 12 Weeks up to Study Completion</title>
            <description>The number of participants with plasma HIV-1 RNA &lt;400 c/mL or &lt;50 c/mL was assessed at Weeks 48, 72, 96, 108, 120, 132, 144, 156, 168, 180, 192, 204, 216, 228, 240, 252, and 264 using data of observed cases. Only those participants available at the specified time points were analyzed (represented by n=X in the category titles).</description>
            <units>Percentage of Participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>Week 48, &lt;50 c/mL, n=15, 20</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="60"/>
                  <measurement group_id="O2" value="80"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Week 60, &lt;50 c/mL, n=13, 18</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="69"/>
                  <measurement group_id="O2" value="94"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Week 72, &lt;50 c/mL, n=14, 18</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="64"/>
                  <measurement group_id="O2" value="78"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Week 84, &lt;50 c/mL, n=14, 18</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="57"/>
                  <measurement group_id="O2" value="78"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Week 96, &lt;50 c/mL, n=13, 15</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="54"/>
                  <measurement group_id="O2" value="87"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Week 108, &lt;50 c/mL, n=13, 17</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="54"/>
                  <measurement group_id="O2" value="88"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Week 120, &lt;50 c/mL, n=11, 17</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="55"/>
                  <measurement group_id="O2" value="88"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Week 132, &lt;50 c/mL, n=11, 17</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="55"/>
                  <measurement group_id="O2" value="82"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Week 144, &lt;50 c/mL, n=12, 15</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="58"/>
                  <measurement group_id="O2" value="87"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Week 156, &lt;50 c/mL, n=12, 15</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="67"/>
                  <measurement group_id="O2" value="93"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Week 168, &lt;50 c/mL, n=11, 14</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="64"/>
                  <measurement group_id="O2" value="86"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Week 180, &lt;50 c/mL, n=11, 10</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="64"/>
                  <measurement group_id="O2" value="100"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Week 192, &lt;50 c/mL, n= 9, 7</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="67"/>
                  <measurement group_id="O2" value="100"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Week 204, &lt;50 c/mL, n= 10, 6</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="50"/>
                  <measurement group_id="O2" value="100"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Week 216, &lt;50 c/mL, n= 9, 6</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="56"/>
                  <measurement group_id="O2" value="100"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Week 228, &lt;50 c/mL, n=6, 4</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="67"/>
                  <measurement group_id="O2" value="100"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Week 240, &lt;50 c/mL, n=7,0</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="57"/>
                  <measurement group_id="O2" value="NA">Since 0 participants were analyzed, no value to present.</measurement>
                </measurement_list>
              </category>
              <category>
                <sub_title>Week 252, &lt;50 c/mL, n=4, 0</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="50"/>
                  <measurement group_id="O2" value="NA">Since 0 participants were analyzed, no value to present.</measurement>
                </measurement_list>
              </category>
              <category>
                <sub_title>Week 264, &lt;50 c/mL, n=1, 0</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="100"/>
                  <measurement group_id="O2" value="NA">Since 0 participants were analyzed, no value to present.</measurement>
                </measurement_list>
              </category>
              <category>
                <sub_title>Week 48, &lt;400 c/mL, n=15, 20</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="73"/>
                  <measurement group_id="O2" value="95"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Week 60,&lt;400 c/mL, n=13, 18</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="92"/>
                  <measurement group_id="O2" value="100"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Week 72,&lt;400 c/mL, n=14, 18</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="79"/>
                  <measurement group_id="O2" value="100"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Week 84,&lt;400 c/mL, n=14, 18</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="71"/>
                  <measurement group_id="O2" value="94"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Week 96,&lt;400 c/mL, n=13, 15</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="85"/>
                  <measurement group_id="O2" value="100"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Week 108,&lt;400 c/mL, n=13,17</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="85"/>
                  <measurement group_id="O2" value="100"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Week 120,&lt;400 c/mL, n=11, 17</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="82"/>
                  <measurement group_id="O2" value="94"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Week 132,&lt;400 c/mL, n=11,17</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="82"/>
                  <measurement group_id="O2" value="94"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Week 144,&lt;400 c/mL, n=12, 15</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="83"/>
                  <measurement group_id="O2" value="93"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Week 156,&lt;400 c/mL, n=12, 15</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="75"/>
                  <measurement group_id="O2" value="100"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Week 168,&lt;400 c/mL, n=11, 14</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="82"/>
                  <measurement group_id="O2" value="100"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Week 180,&lt;400 c/mL, n=11, 10</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="73"/>
                  <measurement group_id="O2" value="100"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Week 192,&lt;400 c/mL, n=9, 7</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="78"/>
                  <measurement group_id="O2" value="100"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Week 204,&lt;400 c/mL, n=10, 6</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="70"/>
                  <measurement group_id="O2" value="100"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Week 216,&lt;400 c/mL, n=9, 6</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="56"/>
                  <measurement group_id="O2" value="100"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Week 228,&lt;400 c/mL, n=6, 4</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="67"/>
                  <measurement group_id="O2" value="100"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Week 240,&lt;400 c/mL, n=7, 0</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="71"/>
                  <measurement group_id="O2" value="NA">Since 0 participants were analyzed, no value to present.</measurement>
                </measurement_list>
              </category>
              <category>
                <sub_title>Week 252,&lt;400 c/mL, n=4, 0</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="50"/>
                  <measurement group_id="O2" value="NA">Since 0 participants were analyzed, no value to present.</measurement>
                </measurement_list>
              </category>
              <category>
                <sub_title>Week 264,&lt;400 c/mL, n=1, 0</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="100"/>
                  <measurement group_id="O2" value="NA">Since 0 participants were analyzed, no value to present.</measurement>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in CD4+ Cell Count at Day 11 and Weeks 4, 12, 24, 48, 72, 96, Week 108 Every 12 Weeks up to Study Completion</title>
        <description>Change from Baseline in CD4+ cell count was assessed at Day 11 and at Weeks 4, 12, 24, 48, 72, 96, 108, 120, 132, 144, 156, 168, 180, 192, 204, 216, 228, 240, 252, and 264 . Study Day 1 was considered as Baseline. Change from Baseline was calculated as the post-Baseline value minus the Baseline value.</description>
        <time_frame>Baseline; Day 11; Weeks 4, 12, 24, 48, 72, 96, from Week 108 every 12 weeks up to study completion</time_frame>
        <safety_issue>No</safety_issue>
        <population>ITT-E Population. Only those participants available at the indicated time points were analyzed (represented by n=X in the category titles).</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort I (DTG 50 mg OD)</title>
            <description>Participants received dolutegravir (DTG) 50 milligrams (mg) once a day (OD).</description>
          </group>
          <group group_id="O2">
            <title>Cohort II (DTG 50 mg BID)</title>
            <description>Participants received DTG 50 mg twice a day (BID).</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="27"/>
                  <measurement group_id="O2" value="24"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Change From Baseline in CD4+ Cell Count at Day 11 and Weeks 4, 12, 24, 48, 72, 96, Week 108 Every 12 Weeks up to Study Completion</title>
            <description>Change from Baseline in CD4+ cell count was assessed at Day 11 and at Weeks 4, 12, 24, 48, 72, 96, 108, 120, 132, 144, 156, 168, 180, 192, 204, 216, 228, 240, 252, and 264 . Study Day 1 was considered as Baseline. Change from Baseline was calculated as the post-Baseline value minus the Baseline value.</description>
            <units>cells per cubic millimeter (mm^3)</units>
            <param>Median</param>
            <dispersion>Full Range</dispersion>
            <category_list>
              <category>
                <sub_title>Baseline, n=27, 24</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="114" lower_limit="44" upper_limit="227"/>
                  <measurement group_id="O2" value="202" lower_limit="19" upper_limit="384"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Day 11, n=27, 24</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="34" lower_limit="2" upper_limit="71"/>
                  <measurement group_id="O2" value="14" lower_limit="0" upper_limit="69"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Week 4, n=27, 24</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="57" lower_limit="33" upper_limit="108"/>
                  <measurement group_id="O2" value="35" lower_limit="8" upper_limit="69"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Week 12, n= 22, 24</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="84" lower_limit="26" upper_limit="124"/>
                  <measurement group_id="O2" value="57" lower_limit="8" upper_limit="103"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Week 24, n=17, 22</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="78" lower_limit="54" upper_limit="175"/>
                  <measurement group_id="O2" value="79" lower_limit="17" upper_limit="147"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Week 48, n=15, 20</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="102" lower_limit="29" upper_limit="160"/>
                  <measurement group_id="O2" value="106" lower_limit="45" upper_limit="245"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Week 72, n=14, 18</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="163" lower_limit="58" upper_limit="204"/>
                  <measurement group_id="O2" value="191.5" lower_limit="80" upper_limit="277"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Week 96, n=13, 15</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="142" lower_limit="75" upper_limit="202"/>
                  <measurement group_id="O2" value="189" lower_limit="75" upper_limit="280"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Week 108, n=13, 17</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="124" lower_limit="68" upper_limit="249"/>
                  <measurement group_id="O2" value="155" lower_limit="91" upper_limit="276"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Week 120, n=11, 17</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="221" lower_limit="62" upper_limit="306"/>
                  <measurement group_id="O2" value="221" lower_limit="135" upper_limit="314"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Week 132, n=11, 17</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="97" lower_limit="26" upper_limit="303"/>
                  <measurement group_id="O2" value="158" lower_limit="129" upper_limit="384"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Week 144, n=12, 15</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="121" lower_limit="28" upper_limit="284"/>
                  <measurement group_id="O2" value="278" lower_limit="113" upper_limit="340"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Week 156, n=12, 15</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="212" lower_limit="64" upper_limit="378"/>
                  <measurement group_id="O2" value="223" lower_limit="131" upper_limit="309"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Week 168, n=11, 13</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="97" lower_limit="-102" upper_limit="365"/>
                  <measurement group_id="O2" value="271" lower_limit="93" upper_limit="357"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Week 180, n=11, 10</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="125" lower_limit="55" upper_limit="327"/>
                  <measurement group_id="O2" value="224" lower_limit="163" upper_limit="288"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Week 192, n=10, 7</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="94" lower_limit="61" upper_limit="291"/>
                  <measurement group_id="O2" value="343" lower_limit="304" upper_limit="429"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Week 204, n=10, 6</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="92" lower_limit="47" upper_limit="364"/>
                  <measurement group_id="O2" value="264" lower_limit="186" upper_limit="370"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Week 216, n=9, 6</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="172" lower_limit="48" upper_limit="416"/>
                  <measurement group_id="O2" value="252" lower_limit="147" upper_limit="421"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Week 228, n=7, 3</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="148" lower_limit="66" upper_limit="357"/>
                  <measurement group_id="O2" value="417" lower_limit="-12" upper_limit="633"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Week 240, n=7, 0</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="158" lower_limit="119" upper_limit="470"/>
                  <measurement group_id="O2" value="NA">Since 0 participants were analyzed, no data to present.</measurement>
                </measurement_list>
              </category>
              <category>
                <sub_title>Week 252, n=4, 0</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="157" lower_limit="109" upper_limit="282"/>
                  <measurement group_id="O2" value="NA">Since 0 participants were analyzed, no data to present.</measurement>
                </measurement_list>
              </category>
              <category>
                <sub_title>Week 264, n=1, 0</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="560" lower_limit="560" upper_limit="560"/>
                  <measurement group_id="O2" value="NA">Since 0 participants were analyzed, no data to present.</measurement>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cmax, Cmin, and Ctau of DTG</title>
        <description>The maximum plasma concentration (Cmax), minimum plasma concentration (Cmin), and concentration at the end of a dosing interval (Ctau) of DTG were assessed at Day 10. Blood samples for pharmacokinetic (PK) assessments were collected at pre-dose (within 15 minutes prior to dose) and 2, 3, 4, 8, and 24 hours post-dose on Day 10 for DTG 50 mg OD and pre-dose (within 15 minutes prior to dose) and 2, 3, 4 and 8 hours post morning dose and 12 hours post evening dose for DTG 50 mg BID.</description>
        <time_frame>Day 10</time_frame>
        <safety_issue>No</safety_issue>
        <population>Pharmacokinetic (PK) Parameter Population: all participants who provided at least one evaluable PK concentration</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort I (DTG 50 mg OD)</title>
            <description>Participants received dolutegravir (DTG) 50 milligrams (mg) once a day (OD).</description>
          </group>
          <group group_id="O2">
            <title>Cohort II (DTG 50 mg BID)</title>
            <description>Participants received DTG 50 mg twice a day (BID).</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="25"/>
                  <measurement group_id="O2" value="23"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Cmax, Cmin, and Ctau of DTG</title>
            <description>The maximum plasma concentration (Cmax), minimum plasma concentration (Cmin), and concentration at the end of a dosing interval (Ctau) of DTG were assessed at Day 10. Blood samples for pharmacokinetic (PK) assessments were collected at pre-dose (within 15 minutes prior to dose) and 2, 3, 4, 8, and 24 hours post-dose on Day 10 for DTG 50 mg OD and pre-dose (within 15 minutes prior to dose) and 2, 3, 4 and 8 hours post morning dose and 12 hours post evening dose for DTG 50 mg BID.</description>
            <units>Micrograms per milliliter (µg/mL)</units>
            <param>Geometric Mean</param>
            <dispersion>Geometric Coefficient of Variation</dispersion>
            <category_list>
              <category>
                <sub_title>Cmax</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="3.04" spread="38"/>
                  <measurement group_id="O2" value="5.41" spread="40"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Ctau</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0.69" spread="91"/>
                  <measurement group_id="O2" value="2.72" spread="70"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Cmin</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0.48" spread="136"/>
                  <measurement group_id="O2" value="2.61" spread="67"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>C0 Assessment of DTG</title>
        <description>The plasma DTG concentration immediately prior to dosing at steady state (C0) was assessed at Day 10, and Weeks 4 and 24. Blood samples for pharmacokinetic assessments were collected at pre-dose (within 15 minutes prior to dose).</description>
        <time_frame>Day 10; Weeks 4 and 24</time_frame>
        <safety_issue>No</safety_issue>
        <population>PK Parameter Population</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort I (DTG 50 mg OD)</title>
            <description>Participants received dolutegravir (DTG) 50 milligrams (mg) once a day (OD).</description>
          </group>
          <group group_id="O2">
            <title>Cohort II (DTG 50 mg BID)</title>
            <description>Participants received DTG 50 mg twice a day (BID).</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="25"/>
                  <measurement group_id="O2" value="23"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>C0 Assessment of DTG</title>
            <description>The plasma DTG concentration immediately prior to dosing at steady state (C0) was assessed at Day 10, and Weeks 4 and 24. Blood samples for pharmacokinetic assessments were collected at pre-dose (within 15 minutes prior to dose).</description>
            <units>µg/mL</units>
            <param>Geometric Mean</param>
            <dispersion>Geometric Coefficient of Variation</dispersion>
            <category_list>
              <category>
                <sub_title>C0, Day 10</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0.51" spread="139"/>
                  <measurement group_id="O2" value="3.20" spread="69"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>C0, Week 4</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0.57" spread="100"/>
                  <measurement group_id="O2" value="2.55" spread="63"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>C0, Week 24</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0.38" spread="114"/>
                  <measurement group_id="O2" value="2.38" spread="69"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Tmax of DTG</title>
        <description>The tmax is defined as the time of occurrence of the maximum plasma concentration (Cmax). The tmax was assessed at Day 10. Blood samples for pharmacokinetic assessments were collected at pre-dose (within 15 minutes prior to dose) and 2, 3, 4, 8, and 24 hours post-dose on Day 10 for DTG 50 mg OD and pre-dose (within 15 minutes prior to dose) and 2, 3, 4 and 8 hours post morning dose and 12 hours post evening dose for DTG 50 mg BID.</description>
        <time_frame>Day 10</time_frame>
        <safety_issue>No</safety_issue>
        <population>PK Parameter Population</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort I (DTG 50 mg OD)</title>
            <description>Participants received dolutegravir (DTG) 50 milligrams (mg) once a day (OD).</description>
          </group>
          <group group_id="O2">
            <title>Cohort II (DTG 50 mg BID)</title>
            <description>Participants received DTG 50 mg twice a day (BID).</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="25"/>
                  <measurement group_id="O2" value="23"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Tmax of DTG</title>
            <description>The tmax is defined as the time of occurrence of the maximum plasma concentration (Cmax). The tmax was assessed at Day 10. Blood samples for pharmacokinetic assessments were collected at pre-dose (within 15 minutes prior to dose) and 2, 3, 4, 8, and 24 hours post-dose on Day 10 for DTG 50 mg OD and pre-dose (within 15 minutes prior to dose) and 2, 3, 4 and 8 hours post morning dose and 12 hours post evening dose for DTG 50 mg BID.</description>
            <units>Hours</units>
            <param>Median</param>
            <dispersion>Full Range</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="2.97" lower_limit="1.97" upper_limit="7.92"/>
                  <measurement group_id="O2" value="2.00" lower_limit="0.00" upper_limit="7.87"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>AUC0-24 Assessment of DTG</title>
        <description>AUC is defined as the area under the DTG concentration-time curve as a measure of drug exposure. AUC(0-24) is defined as the area under the concentration-time curve from time zero (pre-dose) to 24 hours. AUC0-24 of DTG was assessed at Day 10. Blood samples for pharmacokinetic assessments were collected at pre-dose (within 15 minutes prior to dose) and 2, 3, 4, 8, and 24 hours post-dose on Day 10 for DTG 50 mg OD and pre-dose (within 15 minutes prior to dose) and 2, 3, 4 and 8 hours post morning dose and 12 hours post evening dose for DTG 50 mg BID.</description>
        <time_frame>Day 10</time_frame>
        <safety_issue>No</safety_issue>
        <population>PK Parameter Population</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort I (DTG 50 mg OD)</title>
            <description>Participants received dolutegravir (DTG) 50 milligrams (mg) once a day (OD).</description>
          </group>
          <group group_id="O2">
            <title>Cohort II (DTG 50 mg BID)</title>
            <description>Participants received DTG 50 mg twice a day (BID).</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="25"/>
                  <measurement group_id="O2" value="23"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>AUC0-24 Assessment of DTG</title>
            <description>AUC is defined as the area under the DTG concentration-time curve as a measure of drug exposure. AUC(0-24) is defined as the area under the concentration-time curve from time zero (pre-dose) to 24 hours. AUC0-24 of DTG was assessed at Day 10. Blood samples for pharmacokinetic assessments were collected at pre-dose (within 15 minutes prior to dose) and 2, 3, 4, 8, and 24 hours post-dose on Day 10 for DTG 50 mg OD and pre-dose (within 15 minutes prior to dose) and 2, 3, 4 and 8 hours post morning dose and 12 hours post evening dose for DTG 50 mg BID.</description>
            <units>Micrograms*hour per milliliter (µg*hr/mL</units>
            <param>Geometric Mean</param>
            <dispersion>Geometric Coefficient of Variation</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="36.46" spread="53"/>
                  <measurement group_id="O2" value="93.36" spread="50"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With the Indicated HIV-1 Associated Conditions, Excluding Recurrences</title>
        <description>The number of participants with post-Baseline emergent HIV-1 disease progression (Acquired immunodeficiency syndrome (AIDS) or death) was assessed per the Centers for Disease Control and Prevention (CDC) 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. The CDC classifies HIV infection as Category A (participants with asymptomatic HIV infection, acute HIV infection with accompanying illness, or persistent generalized lymphadenopathy), Category B (participants with symptomatic non-AIDS condition, i.e., conditions that are attributed to HIV infection or are indicative of a defect in cell-mediated immunity; or conditions are considered by physicians to have a clinical course or to require management that is complicated by HIV infection), and Category C (includes AIDS indicator conditions as defined by diagnostic or presumptive measures).</description>
        <time_frame>From the day of the first dose of study drug until study completion (median 605 days for Cohort I, median 1181 days for Cohort II)</time_frame>
        <safety_issue>No</safety_issue>
        <population>ITT-E Population. Participant may have more than one HIV associated condition. Each condition is counted only once per participant, regardless of recurrence.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort I (DTG 50 mg OD)</title>
            <description>Participants received dolutegravir (DTG) 50 milligrams (mg) once a day (OD).</description>
          </group>
          <group group_id="O2">
            <title>Cohort II (DTG 50 mg BID)</title>
            <description>Participants received DTG 50 mg twice a day (BID).</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="27"/>
                  <measurement group_id="O2" value="24"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Participants With the Indicated HIV-1 Associated Conditions, Excluding Recurrences</title>
            <description>The number of participants with post-Baseline emergent HIV-1 disease progression (Acquired immunodeficiency syndrome (AIDS) or death) was assessed per the Centers for Disease Control and Prevention (CDC) 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. The CDC classifies HIV infection as Category A (participants with asymptomatic HIV infection, acute HIV infection with accompanying illness, or persistent generalized lymphadenopathy), Category B (participants with symptomatic non-AIDS condition, i.e., conditions that are attributed to HIV infection or are indicative of a defect in cell-mediated immunity; or conditions are considered by physicians to have a clinical course or to require management that is complicated by HIV infection), and Category C (includes AIDS indicator conditions as defined by diagnostic or presumptive measures).</description>
            <units>Participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>Category B, Candidiasis, oropharyngeal</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="3"/>
                  <measurement group_id="O2" value="2"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Category B, Hairy leukoplakia, oral</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Category B, Herpes Zoster</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Category C, Herpes simplex</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Category C, Candidiasis, esophageal</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Category C, Cytomegalovirus retinitis</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Category C, Kaposi's sarcoma</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Category C, Lymphoma, Burkitt's</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Category C, Lymphoma, immunoblastic</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Death, Brain mass</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Death, Completed suicide</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Death, Febrile bone marrow aplasia</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Death, Immunoblastic lymphoma</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Death, Acute pulmonary oedema</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Death, Anaemia</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Death, Haemochromatosis</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Death, Hepatic fibrosis</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Other: Cryptosporidiosis, acute intestinal</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Other: leukoplasia of both side of the tongue</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With HIV-1 Associated Disease Progression With the Indicated Shifts to CDC Class C or Death</title>
        <description>The number of participants with HIV-1 disease progression (AIDS or death) was assessed per the CDC 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. The CDC classifies HIV infection as Category A (participants with asymptomatic HIV infection, acute HIV infection with accompanying illness, or persistent generalized lymphadenopathy), Category B (participants with symptomatic non-AIDS condition, i.e., conditions that are attributed to HIV infection or are indicative of a defect in cell-mediated immunity; or conditions are considered by physicians to have a clinical course or to require management that is complicated by HIV infection), and Category C (includes AIDS indicator conditions as defined by diagnostic or presumptive measures).</description>
        <time_frame>From the day of the first dose of study drug until study completion (median 605 days for Cohort I, median 1181 days for Cohort II)</time_frame>
        <safety_issue>No</safety_issue>
        <population>ITT-E Population.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort I (DTG 50 mg OD)</title>
            <description>Participants received dolutegravir (DTG) 50 milligrams (mg) once a day (OD).</description>
          </group>
          <group group_id="O2">
            <title>Cohort II (DTG 50 mg BID)</title>
            <description>Participants received DTG 50 mg twice a day (BID).</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="27"/>
                  <measurement group_id="O2" value="24"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Participants With HIV-1 Associated Disease Progression With the Indicated Shifts to CDC Class C or Death</title>
            <description>The number of participants with HIV-1 disease progression (AIDS or death) was assessed per the CDC 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. The CDC classifies HIV infection as Category A (participants with asymptomatic HIV infection, acute HIV infection with accompanying illness, or persistent generalized lymphadenopathy), Category B (participants with symptomatic non-AIDS condition, i.e., conditions that are attributed to HIV infection or are indicative of a defect in cell-mediated immunity; or conditions are considered by physicians to have a clinical course or to require management that is complicated by HIV infection), and Category C (includes AIDS indicator conditions as defined by diagnostic or presumptive measures).</description>
            <units>Participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>From CDC class A to CDC class C</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="2"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>From CDC class B to CDC class C</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="2"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>From CDC class C to new CDC class C</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>From CDC Class A, B, or C to death</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="3"/>
                  <measurement group_id="O2" value="2"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants (Cumulative) With Protocol-defined Virological Failure (PDVF) at Day 11 and Weeks 8, 12, 16, 20, 24, 32, 40, 48, 60, 72, 84, 96, Week 108 Every 12 Weeks up to Study Completion</title>
        <description>PDVF is defined in relation to Baseline plasma HIV-1 RNA levels: at Day 11, a decrease of &lt;0.7 log10 c/mL unless &lt;400 c/mL; at Weeks 8 to &lt;16, a decrease of &lt;1.0 log10 c/mL unless &lt;400 c/mL or an increase of &gt;= 1.0 log10 c/mL from nadir; and at or after Week 16, ≥400 c/mL. PDVF at Day 11 was based on a single plasma HIV-1 RNA evaluation and did not require confirmation. Confirmation testing was required for visits at or after Week 8. For the combination treatment phase, all HIV-1 RNA samples that meet a criterion for suspected PDVF must be confirmed by a second measurement performed at least 1 week but not more than 4 weeks apart from the date of the original sample.</description>
        <time_frame>Day 11; Weeks 8, 12, 16, 20, 24, 32, 40, 48, 60, 72, 84, 96, from Week 108 every 12 weeks up to study completion</time_frame>
        <safety_issue>No</safety_issue>
        <population>ITT-E Population</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort I (DTG 50 mg OD)</title>
            <description>Participants received dolutegravir (DTG) 50 milligrams (mg) once a day (OD).</description>
          </group>
          <group group_id="O2">
            <title>Cohort II (DTG 50 mg BID)</title>
            <description>Participants received DTG 50 mg twice a day (BID).</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="27"/>
                  <measurement group_id="O2" value="24"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Participants (Cumulative) With Protocol-defined Virological Failure (PDVF) at Day 11 and Weeks 8, 12, 16, 20, 24, 32, 40, 48, 60, 72, 84, 96, Week 108 Every 12 Weeks up to Study Completion</title>
            <description>PDVF is defined in relation to Baseline plasma HIV-1 RNA levels: at Day 11, a decrease of &lt;0.7 log10 c/mL unless &lt;400 c/mL; at Weeks 8 to &lt;16, a decrease of &lt;1.0 log10 c/mL unless &lt;400 c/mL or an increase of &gt;= 1.0 log10 c/mL from nadir; and at or after Week 16, ≥400 c/mL. PDVF at Day 11 was based on a single plasma HIV-1 RNA evaluation and did not require confirmation. Confirmation testing was required for visits at or after Week 8. For the combination treatment phase, all HIV-1 RNA samples that meet a criterion for suspected PDVF must be confirmed by a second measurement performed at least 1 week but not more than 4 weeks apart from the date of the original sample.</description>
            <units>Participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>Day 11</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="6"/>
                  <measurement group_id="O2" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Week 8</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="7"/>
                  <measurement group_id="O2" value="3"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Week 12</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="9"/>
                  <measurement group_id="O2" value="3"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Week 16</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="10"/>
                  <measurement group_id="O2" value="5"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Week 20</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="10"/>
                  <measurement group_id="O2" value="5"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Week 24</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="12"/>
                  <measurement group_id="O2" value="5"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Week 32</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="12"/>
                  <measurement group_id="O2" value="5"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Week 40</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="12"/>
                  <measurement group_id="O2" value="5"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Week 48</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="13"/>
                  <measurement group_id="O2" value="5"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Week 60</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="13"/>
                  <measurement group_id="O2" value="5"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Week 72</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="14"/>
                  <measurement group_id="O2" value="6"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Week 84</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="15"/>
                  <measurement group_id="O2" value="6"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Week 96</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="16"/>
                  <measurement group_id="O2" value="6"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Week 108</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="16"/>
                  <measurement group_id="O2" value="6"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Week 120</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="16"/>
                  <measurement group_id="O2" value="6"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Week 132</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="16"/>
                  <measurement group_id="O2" value="6"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Week 144</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="16"/>
                  <measurement group_id="O2" value="7"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Week 156</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="16"/>
                  <measurement group_id="O2" value="7"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Week 168</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="16"/>
                  <measurement group_id="O2" value="7"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Week 180</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="16"/>
                  <measurement group_id="O2" value="7"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Week 192</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="16"/>
                  <measurement group_id="O2" value="7"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Week 204</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="16"/>
                  <measurement group_id="O2" value="7"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Week 216</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="17"/>
                  <measurement group_id="O2" value="7"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Week 228</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="18"/>
                  <measurement group_id="O2" value="7"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Week 240</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="18"/>
                  <measurement group_id="O2" value="NA">No data were available for analysis from Cohort II at the time points.</measurement>
                </measurement_list>
              </category>
              <category>
                <sub_title>Week 252</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="18"/>
                  <measurement group_id="O2" value="NA">No data were available for analysis from Cohort II at the time points.</measurement>
                </measurement_list>
              </category>
              <category>
                <sub_title>Week 264</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="18"/>
                  <measurement group_id="O2" value="NA">No data were available for analysis from Cohort II at the time points.</measurement>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With the Indicated Genotypic Resistance at Baseline</title>
        <description>At Baseline, the integrase genotypic results were used to document resistance to raltegravir (RAL) and for the allocation of participants to one of two genotypic groups according to their RAL signature mutations to ensure a broad range of sensitivity to DTG. These results were not used to pre-define subgroup for analysis.</description>
        <time_frame>Baseline</time_frame>
        <safety_issue>No</safety_issue>
        <population>ITT-E Population</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort I (DTG 50 mg OD)</title>
            <description>Participants received dolutegravir (DTG) 50 milligrams (mg) once a day (OD).</description>
          </group>
          <group group_id="O2">
            <title>Cohort II (DTG 50 mg BID)</title>
            <description>Participants received DTG 50 mg twice a day (BID).</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="27"/>
                  <measurement group_id="O2" value="24"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Participants With the Indicated Genotypic Resistance at Baseline</title>
            <description>At Baseline, the integrase genotypic results were used to document resistance to raltegravir (RAL) and for the allocation of participants to one of two genotypic groups according to their RAL signature mutations to ensure a broad range of sensitivity to DTG. These results were not used to pre-define subgroup for analysis.</description>
            <units>Participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>Q148 + 2</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="3"/>
                  <measurement group_id="O2" value="2"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Q 148 + 1</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="4"/>
                  <measurement group_id="O2" value="8"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Mixture</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2"/>
                  <measurement group_id="O2" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Y143</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="12"/>
                  <measurement group_id="O2" value="6"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>N155</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="4"/>
                  <measurement group_id="O2" value="6"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Other</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2"/>
                  <measurement group_id="O2" value="1"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Median Fold Change in Sensitivity to DTG by the Baseline (Day 1) IN Mutational Group</title>
        <description>Summary of median fold change in sensitivity to DTG by Integrase (IN) mutational group was assessed. The IN mutational group comprises of the following mutations: Q148 +2, Q148 +1, mixture (participants with virus containing more than one Y143, Q148 or N155 mutation at Day 1), Y143, N155, other (participants with virus having no mutations at codons 143, 148, or 155 at Day 1). Fold change (FC) is the fold change in 50% Inhibitory Concentration (IC50) relative to the wild-type control virus.</description>
        <time_frame>Baseline (Day 1)</time_frame>
        <safety_issue>No</safety_issue>
        <population>ITT-E Population</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort I (DTG 50 mg OD)</title>
            <description>Participants received dolutegravir (DTG) 50 milligrams (mg) once a day (OD).</description>
          </group>
          <group group_id="O2">
            <title>Cohort II (DTG 50 mg BID)</title>
            <description>Participants received DTG 50 mg twice a day (BID).</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="27"/>
                  <measurement group_id="O2" value="24"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Median Fold Change in Sensitivity to DTG by the Baseline (Day 1) IN Mutational Group</title>
            <description>Summary of median fold change in sensitivity to DTG by Integrase (IN) mutational group was assessed. The IN mutational group comprises of the following mutations: Q148 +2, Q148 +1, mixture (participants with virus containing more than one Y143, Q148 or N155 mutation at Day 1), Y143, N155, other (participants with virus having no mutations at codons 143, 148, or 155 at Day 1). Fold change (FC) is the fold change in 50% Inhibitory Concentration (IC50) relative to the wild-type control virus.</description>
            <units>Percentage</units>
            <param>Median</param>
            <dispersion>Full Range</dispersion>
            <category_list>
              <category>
                <sub_title>Q148 + 2, n=3, 2</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="21" lower_limit="14" upper_limit="35"/>
                  <measurement group_id="O2" value="4" lower_limit="2.1" upper_limit="6.0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Q148 + 1, n=4, 8</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="5.5" lower_limit="3.3" upper_limit="25"/>
                  <measurement group_id="O2" value="5.5" lower_limit="4.1" upper_limit="8.2"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Mixture, n=2, 1</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="7.8" lower_limit="6.5" upper_limit="9.1"/>
                  <measurement group_id="O2" value="9.48" lower_limit="9.48" upper_limit="9.48"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Y143, n=12, 6</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1.1" lower_limit="0.6" upper_limit="1.4"/>
                  <measurement group_id="O2" value="1.2" lower_limit="0.92" upper_limit="1.8"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>N155, n=4, 6</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1.8" lower_limit="1.5" upper_limit="5.1"/>
                  <measurement group_id="O2" value="2.3" lower_limit="1.3" upper_limit="4.0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Other, n=2, 1</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1.2" lower_limit="0.9" upper_limit="1.5"/>
                  <measurement group_id="O2" value="0.87" lower_limit="0.87" upper_limit="0.87"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With the Indicated Treatment-emergent Integrase (IN) Mutations Detected at the Time of Protocol-defined Virologic Failure (PDVF) as a Measure of Genotypic Resistance</title>
        <description>An analysis of changes at specific amino acids in the IN coding region associated with resistance to raltegravir, elvitegravir, or DTG was performed at Day 1 and at the time of PDVF. PDVF is defined in relation to Baseline plasma HIV-1 RNA levels: at Day 11, a decrease of &lt;0.7 log10 c/mL unless &lt;400 c/mL; at Weeks 8 to &lt;16, a decrease of &lt;1.0 log10 c/mL unless &lt;400 c/mL or an increase of &gt;= 1.0 log10 c/mL from nadir; and at or after Week 16, ≥400 c/mL. PDVF at Day 11 was based on a single plasma HIV-1 RNA evaluation and did not require confirmation. Confirmation testing was required for visits at or after Week 8. For the combination treatment phase, all HIV-1 RNA samples that meet a criterion for suspected PDVF must be confirmed by a second measurement performed at least 1 week but not more than 4 weeks apart from the date of the original sample.</description>
        <time_frame>From Baseline (Day 1) until study completion (median 605 days for Cohort I, median 1181 days for Cohort II)</time_frame>
        <safety_issue>No</safety_issue>
        <population>On-treatment Genotypic Resistance Population: all ITT-E participants who met the criteria for protocol-defined virological failure (PDVF)</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort I (DTG 50 mg OD)</title>
            <description>Participants received dolutegravir (DTG) 50 milligrams (mg) once a day (OD).</description>
          </group>
          <group group_id="O2">
            <title>Cohort II (DTG 50 mg BID)</title>
            <description>Participants received DTG 50 mg twice a day (BID).</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="18"/>
                  <measurement group_id="O2" value="7"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Participants With the Indicated Treatment-emergent Integrase (IN) Mutations Detected at the Time of Protocol-defined Virologic Failure (PDVF) as a Measure of Genotypic Resistance</title>
            <description>An analysis of changes at specific amino acids in the IN coding region associated with resistance to raltegravir, elvitegravir, or DTG was performed at Day 1 and at the time of PDVF. PDVF is defined in relation to Baseline plasma HIV-1 RNA levels: at Day 11, a decrease of &lt;0.7 log10 c/mL unless &lt;400 c/mL; at Weeks 8 to &lt;16, a decrease of &lt;1.0 log10 c/mL unless &lt;400 c/mL or an increase of &gt;= 1.0 log10 c/mL from nadir; and at or after Week 16, ≥400 c/mL. PDVF at Day 11 was based on a single plasma HIV-1 RNA evaluation and did not require confirmation. Confirmation testing was required for visits at or after Week 8. For the combination treatment phase, all HIV-1 RNA samples that meet a criterion for suspected PDVF must be confirmed by a second measurement performed at least 1 week but not more than 4 weeks apart from the date of the original sample.</description>
            <units>Participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>Any</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="11"/>
                  <measurement group_id="O2" value="5"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>E138T</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>N155H</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="3"/>
                  <measurement group_id="O2" value="4"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>T97A</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>E92E/Q</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>G140S</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="3"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>L74I/M</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Q148H</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>E138E/A</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>E138E/K</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="2"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>L74I/M/I</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>L74M</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>L74I</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>T97T/A</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="2"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Q148R</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>S147G</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="3"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>E92E/V</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>L68L/I</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With the Indicated Fold Increase in DTG FC (Fold Change in IC50 Relative to Wild-type Virus) Between Baseline and the Time of PDVF, as a Measure of Post-Baseline Phenotypic Resistance</title>
        <description>The FC in IC50 (50% inhibitory concentration) for DTG relative to wild-type virus was determined for virus isolated at Baseline and at the time of PDVF.The number of participants with the indicated change (ratio) in the two values at the time of PDVF is presented. PDVF is defined in relation to Baseline plasma HIV-1 RNA levels: at Day 11, a decrease of &lt;0.7 log 10 c/mL unless &lt;400 c/mL; at Weeks 8 to &lt;16, a decrease of &lt;1.0 log 10 c/mL unless &lt;400 c/mL or an increase of &gt;=1.0 log 10 c/mL from nadir; and at or after Week 16, ≥400 c/mL . PDVF at Day 11 was based on a single plasma HIV-1 RNA evaluation and did not require confirmation. Confirmation testing was required for visits at or after Week 8. For the combination treatment phase, all HIV-1 RNA samples that meet a criterion for suspected PDVF must be confirmed by a second measurement performed at least 1 week but not more than 4 weeks apart from the date of original sample.</description>
        <time_frame>From Baseline (Day 1) until study completion (median 605 days for Cohort I, median 1181 days for Cohort II)</time_frame>
        <safety_issue>No</safety_issue>
        <population>PDVF Phenotypic Resistance Populations: all participants in the ITT-E Population with available on-treatment phenotypic resistance data at the time of PDVF failure. Only participants with both Baseline and PDVF time-point DTG phenotypic data were considered for analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort I (DTG 50 mg OD)</title>
            <description>Participants received dolutegravir (DTG) 50 milligrams (mg) once a day (OD).</description>
          </group>
          <group group_id="O2">
            <title>Cohort II (DTG 50 mg BID)</title>
            <description>Participants received DTG 50 mg twice a day (BID).</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="17"/>
                  <measurement group_id="O2" value="7"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Participants With the Indicated Fold Increase in DTG FC (Fold Change in IC50 Relative to Wild-type Virus) Between Baseline and the Time of PDVF, as a Measure of Post-Baseline Phenotypic Resistance</title>
            <description>The FC in IC50 (50% inhibitory concentration) for DTG relative to wild-type virus was determined for virus isolated at Baseline and at the time of PDVF.The number of participants with the indicated change (ratio) in the two values at the time of PDVF is presented. PDVF is defined in relation to Baseline plasma HIV-1 RNA levels: at Day 11, a decrease of &lt;0.7 log 10 c/mL unless &lt;400 c/mL; at Weeks 8 to &lt;16, a decrease of &lt;1.0 log 10 c/mL unless &lt;400 c/mL or an increase of &gt;=1.0 log 10 c/mL from nadir; and at or after Week 16, ≥400 c/mL . PDVF at Day 11 was based on a single plasma HIV-1 RNA evaluation and did not require confirmation. Confirmation testing was required for visits at or after Week 8. For the combination treatment phase, all HIV-1 RNA samples that meet a criterion for suspected PDVF must be confirmed by a second measurement performed at least 1 week but not more than 4 weeks apart from the date of original sample.</description>
            <units>Participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>&lt;1 fold</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="3"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>1-&lt;2 fold</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="4"/>
                  <measurement group_id="O2" value="2"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>2-&lt;4 fold</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>4-&lt;8 fold</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="2"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>&gt;=8 fold</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="8"/>
                  <measurement group_id="O2" value="3"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With the Indicated Grade 3 and Grade 4 Clinical Chemistry Toxicities</title>
        <description>Hematology and clinical chemistry data were summarized according to Division of AIDS (DAIDS) Table for Grading the Severity of Adult and Pediatric Adverse Events, dated December 2004. Grade 1, Mild; Grade 2, Moderate; Grade 3, Severe; Grade 4, Potentially life-threatening. Data are presented for only those parameters for which an increase to Grade 3 or Grade 4 occurred. The Grade 3 and Grade 4 clinical chemistry toxicities included: Albumin, Alkaline Phosphatase, Amylase, Aspartate Amino Transferase, Carbon dioxide content/Bicarbonate, Creatinine, Creatinine Clearance, Hypercalcemia, Hyperglycaemia, Hyperkalemia, Hypernatremia, Hypocalcemia, Hypoglycaemia, Hypokalemia, Hyponatremia, LDL Cholesterol, Magnesium, Phosphorus inorganic, and Total Bilirubin, Alanine Amino Transferase, Calcium, Chloride, Cholesterol, Creatine Kinase, Direct Bilirubin, Glucose, High Density Lipid (HDL), Cholesterol direct, Lipase, Potassium, Sodium, Total Cholesterol, Triglycerides, Urea/Blood Urine Nitrogen.</description>
        <time_frame>From start of study treatment until the end of treatment visit for each participant, up to Week 264 for Cohort I and up to Week 228 for Cohort II</time_frame>
        <safety_issue>No</safety_issue>
        <population>Safety Population: all participants that took at least one dose of DTG</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort I (DTG 50 mg OD)</title>
            <description>Participants received dolutegravir (DTG) 50 milligrams (mg) once a day (OD).</description>
          </group>
          <group group_id="O2">
            <title>Cohort II (DTG 50 mg BID)</title>
            <description>Participants received DTG 50 mg twice a day (BID).</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="27"/>
                  <measurement group_id="O2" value="24"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Participants With the Indicated Grade 3 and Grade 4 Clinical Chemistry Toxicities</title>
            <description>Hematology and clinical chemistry data were summarized according to Division of AIDS (DAIDS) Table for Grading the Severity of Adult and Pediatric Adverse Events, dated December 2004. Grade 1, Mild; Grade 2, Moderate; Grade 3, Severe; Grade 4, Potentially life-threatening. Data are presented for only those parameters for which an increase to Grade 3 or Grade 4 occurred. The Grade 3 and Grade 4 clinical chemistry toxicities included: Albumin, Alkaline Phosphatase, Amylase, Aspartate Amino Transferase, Carbon dioxide content/Bicarbonate, Creatinine, Creatinine Clearance, Hypercalcemia, Hyperglycaemia, Hyperkalemia, Hypernatremia, Hypocalcemia, Hypoglycaemia, Hypokalemia, Hyponatremia, LDL Cholesterol, Magnesium, Phosphorus inorganic, and Total Bilirubin, Alanine Amino Transferase, Calcium, Chloride, Cholesterol, Creatine Kinase, Direct Bilirubin, Glucose, High Density Lipid (HDL), Cholesterol direct, Lipase, Potassium, Sodium, Total Cholesterol, Triglycerides, Urea/Blood Urine Nitrogen.</description>
            <units>Participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>Albumin, Grade 3</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Albumin, Grade 4</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Alkaline Phosphatase, Grade 3</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Alkaline Phosphatase, Grade 4</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Amylase, Grade 3</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="2"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Amylase, Grade 4</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Aspartate Amino Transferase, Grade 3</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Aspartate Amino Transferase, Grade 4</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Carbon dioxide content/Bicarbonate, Grade 3</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Carbon dioxide content/Bicarbonate, Grade 4</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Creatinine, Grade 3</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Creatinine, Grade 4</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Creatinine Clearance, estimated, Grade 3</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Creatinine Clearance, estimated, Grade 4</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Hypercalcemia, Grade 3</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Hypercalcemia, Grade 4</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Hyperglycaemia, Grade 3</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Hyperglycaemia, Grade 4</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Hyperkalemia, Grade 3</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Hyperkalemia, Grade 4</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Hypernatremia, Grade 3</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Hypernatremia, Grade 4</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Hypocalcemia, Grade 3</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Hypocalcemia, Grade 4</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Hypoglycaemia, Grade 3</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Hypoglycaemia, Grade 4</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Hypokalemia, Grade 3</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Hypokalemia, Grade 4</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Hyponatremia, Grade 3</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Hyponatremia, Grade 4</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>LDL Cholesterol, Grade 3</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2"/>
                  <measurement group_id="O2" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>LDL Cholesterol, Grade 4</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Magnesium, Grade 3</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Magnesium, Grade 4</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Phosphorus inorganic, Grade 3</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="4"/>
                  <measurement group_id="O2" value="3"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Phosphorus inorganic, Grade 4</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Total Bilirubin, Grade 3</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="2"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Total Bilirubin, Grade 4</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Alanine Amino Transferase ,Grade 3</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Alanine Amino Transferase ,Grade 4</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Calcium,Grade 3</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Calcium,Grade 4</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Chloride,Grade 3</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Chloride,Grade 4</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Cholesterol,Grade 3</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Cholesterol,Grade 4</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Creatine Kinase,Grade 3</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Creatine Kinase,Grade 4</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Direct Bilirubin,Grade 3</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Direct Bilirubin,Grade 4</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Glucose,Grade 3</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Glucose,Grade 4</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>HDL Cholesterol direct,Grade 3</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>HDL Cholesterol direct,Grade 4</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Lipase,Grade 3</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2"/>
                  <measurement group_id="O2" value="3"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Lipase,Grade 4</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Potassium,Grade 3</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Potassium,Grade 4</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Sodium,Grade 3</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Sodium,Grade 4</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Total Cholesterol/HDLratio, Grade 3</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Total Cholesterol/HDLratio, Grade 4</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Triglycerides,Grade 3</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="2"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Triglycerides,Grade 4</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Urea/BUN,Grade 3</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Urea/BUN,Grade 4</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With the Indicated Grade 3 and Grade 4 Hematological Toxicities</title>
        <description>Hematology and clinical chemistry data were summarized according to Division of AIDS (DAIDS) Table for Grading the Severity of Adult and Pediatric Adverse Events, dated December 2004. Grade 1, Mild; Grade 2, Moderate; Grade 3, Severe; Grade 4, Potentially life-threatening. Data are presented for only those parameters for which an increase to Grade 3 or Grade 4 occurred. The Grade 3 and Grade 4 hematological toxicities included: Hemoglobin, Platelet Count, Total Neutrophils, and White Blood Cell count.</description>
        <time_frame>From start of study treatment until the end of treatment visit for each participant, up to Week 264 for Cohort I and up to Week 228 for Cohort II</time_frame>
        <safety_issue>No</safety_issue>
        <population>Safety Population: all participants that took at least one dose of DTG</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort I (DTG 50 mg OD)</title>
            <description>Participants received dolutegravir (DTG) 50 milligrams (mg) once a day (OD).</description>
          </group>
          <group group_id="O2">
            <title>Cohort II (DTG 50 mg BID)</title>
            <description>Participants received DTG 50 mg twice a day (BID).</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="27"/>
                  <measurement group_id="O2" value="24"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Participants With the Indicated Grade 3 and Grade 4 Hematological Toxicities</title>
            <description>Hematology and clinical chemistry data were summarized according to Division of AIDS (DAIDS) Table for Grading the Severity of Adult and Pediatric Adverse Events, dated December 2004. Grade 1, Mild; Grade 2, Moderate; Grade 3, Severe; Grade 4, Potentially life-threatening. Data are presented for only those parameters for which an increase to Grade 3 or Grade 4 occurred. The Grade 3 and Grade 4 hematological toxicities included: Hemoglobin, Platelet Count, Total Neutrophils, and White Blood Cell count.</description>
            <units>Participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>Hemoglobin, Grade 3</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Hemoglobin, Grade 4</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Platelet count, Grade 3</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Platelet count, Grade 4</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Total Neutrophils, Grade 3</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Total Neutrophils, Grade 4</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="2"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>White Blood Cell count, Grade 3</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>White Blood Cell, Grade 4</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="1"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>SAEs, non-serious AEs and laboratory toxicities were collected from start of study treatment until the end of treatment visit for each participant, up to Week 264 for Cohort I and up to Week 228 for Cohort II.</time_frame>
      <desc>SAEs and non-serious AEs were collected in the Safety Population, comprised of all participants that took at least one dose of DTG.</desc>
      <group_list>
        <group group_id="E1">
          <title>Cohort I (DTG 50 mg OD)</title>
          <description>Participants received dolutegravir (DTG) 50 milligrams (mg) once a day (OD).</description>
        </group>
        <group group_id="E2">
          <title>Cohort II (DTG 50 mg BID)</title>
          <description>Participants received DTG 50 mg twice a day (BID).</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Febrile bone marrow aplasia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Febrile neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Coronary artery disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Left ventricular dysfunction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperthyroidism</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Thyroiditis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Dacryostenosis acquired</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Anogenital dysplasia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest discomfort</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Hepatic fibrosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Hepatic cirrhosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Gastroenteritis viral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Neurosyphilis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Staphylococcal abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Diabetes mellitus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Haemochromatosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Hypoalbuminaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Body fat disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Central nervous system lymphoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Immunoblastic lymphoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Uterine leiomyoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>B-cell lymphoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Breast cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Brain mass</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Demyelinating polyneuropathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Convulsion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Completed suicide</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal failure acute</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Acute pulmonary oedema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Cryoglobulinaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="25" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="22" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Lymphadenopathy</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Gastrooesophageal reflux disease</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Abdominal distension</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Defaecation urgency</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Anogenital dysplasia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Influenza like illness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Injection site reaction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Oedema peripherial</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Malaise</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Seasonal allergy</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Rhinitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Herpes virus infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Oral herpes</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Tooth abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Gastroenteritis viral</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Ear infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Genital herpes</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Otitis media</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Lipase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Weight decreased</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Hypercholesterolaemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Vitamin D deficiency</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Backpain</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Muscle spasms</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Tendonitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Anogenital warts</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Sciatica</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Dysaesthesia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Depressed mood</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Pollakiuria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Sinus congestion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Rhinorrhoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Nasal congestion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Hyperhidrosis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Intertrigo</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>GSK Response Center</name_or_title>
      <organization>ViiV Healthcare</organization>
      <phone>866-435-7343</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>
